These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30926637)

  • 21. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
    Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
    Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
    [No Abstract]   [Full Text] [Related]  

  • 24. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 25. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6‑mediated pathways in vivo and in vitro.
    Shi GH; Zhou L
    Mol Med Rep; 2018 Dec; 18(6):5191-5197. PubMed ID: 30272291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.
    Une N; Takano-Kasuya M; Kitamura N; Ohta M; Inose T; Kato C; Nishimura R; Tada H; Miyagi S; Ishida T; Unno M; Kamei T; Gonda K
    Med Oncol; 2021 Apr; 38(6):60. PubMed ID: 33881631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
    Ohkubo JI; Takahashi A; Ikezaki S; Takenaga F; Ohkubo Y; Suzuki H
    Kurume Med J; 2018 Feb; 64(1.2):29-33. PubMed ID: 29057760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer.
    Gong Z; Xue L; Wei M; Liu Z; Vlantis AC; van Hasselt CA; Chan JYK; Li D; Zeng X; Tong MCF; Chen GG
    Oxid Med Cell Longev; 2021; 2021():3900330. PubMed ID: 34527171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
    Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
    Luongo C; Porcelli T; Sessa F; De Stefano MA; Scavuzzo F; Damiano V; Klain M; Bellevicine C; Matano E; Troncone G; Schlumberger M; Salvatore D
    Curr Oncol; 2021 Dec; 28(6):5401-5407. PubMed ID: 34940089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
    Wunderlich A; Khoruzhyk M; Roth S; Ramaswamy A; Greene BH; Doll D; Bartsch DK; Hoffmann S
    J Surg Res; 2013 Dec; 185(2):676-83. PubMed ID: 23845866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenvatinib Administration for Anaplastic Thyroid Carcinoma with Brain Metastasis.
    Obayashi A; Aoki K; Wada T; Furuie H; Kuraoka K; Hamamoto T; Tatsukawa T
    Acta Med Okayama; 2023 Apr; 77(2):227-232. PubMed ID: 37094963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
    Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
    Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
    BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Date E; Okamoto K; Fumita S; Kaneda H
    Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
    Higashiyama T; Sugino K; Hara H; Ito KI; Nakashima N; Onoda N; Tori M; Katoh H; Kiyota N; Ota I; Suganuma N; Hibi Y; Nemoto T; Takahashi S; Yane K; Ioji T; Kojima S; Kaneda H; Sugitani I; Tahara M
    Eur J Cancer; 2022 Sep; 173():210-218. PubMed ID: 35932627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
    Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
    Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
    Boudin L; Morvan JB; Thariat J; Métivier D; Marcy PY; Delarbre D
    Curr Oncol; 2022 Oct; 29(10):7718-7731. PubMed ID: 36290887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
    Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
    Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.